SOURCE: Elsevier Business Intelligence

Elsevier Business Intelligence

October 29, 2012 10:26 ET

Therapeutic Area Partnerships Feature Pharma Leaders Who Unveil How to Pick Drug Targets, Partners, and Deal Models Most Likely to Succeed

BRIDGEWATER, NJ--(Marketwire - Oct 29, 2012) - Elsevier Business Intelligence hosts the 7th Annual Therapeutic Area Partnerships (TAP) at The Westin Copley Place in Boston, MA on November 28-30, 2012. TAP is the industry's most efficient boutique partnering meeting for biopharmaceutical companies and executives seeking to understand, within their therapeutic area portfolio, the strategic outlook for new products in development, alliance opportunities, and current industry pipeline needs and future projections.

Pharma leaders come together for Roundtable Discussions and Q&A that get to the heart of the issues driving each therapeutic area. Alan Crane, General Partner, Polaris Ventures will moderate a unprecedented panel of experts which includes Robert S. Langer, David H. Koch Institute Professor, MIT and Founder, 24+ Companies, Barbara Yanni, Vice President, Chief Licensing Officer, Merck & Co., Inc., Nigel Sheail, Head of Global Business Development & Licensing, Bayer HealthCare AG, Damien McDevitt PhD, Vice President & Head of Business Development for R&D Therapy Area Worldwide Business Development, GlaxoSmithKline, and Graham R. Brazier, Vice President, Business Development Strategic Transactions Group, Bristol-Myers Squibb Company. Panelists will discuss creating new opportunities and partnerships in each therapeutic category, with practical advice on how to find the right drugs and the right partners. Gain insights into partnering and M&A trends and analysis, and understand the specifics driving biopharma deal-making to better calibrate ongoing negotiations. 

Every year respected independent experts rigorously review projects available for partnering and select the top 10 projects in each therapeutic area based on the likelihood of their success as future products. Each clinical advisor will explain the selection process and criteria and briefly describe the programs and companies chosen to present. In the past, many presenting companies in previous years have gone on to establish major partnerships. 

The companies confirmed to present their project this year are: BIND Biosciences, Macrogenics, Apogenix, MEI Pharma, Ceres Oncology, Jennerex Biotherapeutics, Shape Pharmaceuticals, Resverlogix, Aastrom Biosciences, Inc., ARMGO Pharma, Inc., Catabasis Pharmaceuticals, Inc., CardioVascular BioTherapeutics, Inc., Vitae Pharmaceuticals, Esperion, Cortendo, Chimerix, Agenus Bio, Theraclone Sciences, Biota, Novavax, CrystalGenomics, Inc., Alios BioPharma, Virobay, Inc., Array BioPharma, Tigenix, Viacyte, Ambit Biosciences Corporation, Naurex, EnVivo Pharmaceuticals, Zalicus, Allon Therapeutics, Addex Therapeutics, BioAxone BioSciences Inc., Afferent Pharmaceuticals, Neuren Pharmaceuticals, Galenea Corp., Agile Therapeutics, Cytokinetics, Hygeia Therapeutics, OvaScience, AllTranz, GTx, Inc., Prosensa, Sarepta Therapeutics, Akebia Therapeutics, Selecta Biosciences, and KaloBios Pharmaceuticals, Inc.

TAP is a one-of-a-kind opportunity to assess some of the most promising drugs in development and available for partnering in Oncology, Cardiovascular/Metabolic Diseases, Neuroscience, Infectious Diseases, Autoimmune/Anti-Inflammatory Diseases, and Hot Space. Decision-makers focusing on these therapeutic categories can meet to develop strategic alliances between their companies. Utilize our partnering software to conduct research on companies you might wish to meet at the conference, schedule one-on-one meetings with prospective partners, and showcase your company's innovative technology and investment/partnering interests. Attend TAP this year and walk away with real opportunities for lucrative acquisitions and alliances. For more information or to register for this event, visit www.tapartnerships.com.

About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact Information

  • Media contact:
    Mike Fergus
    Elsevier Business Intelligence
    908-547-2167
    Email Contact